Early Sedation with Dexmedetomidine in Critically Ill Patients
Y Shehabi, BD Howe, R Bellomo, YM Arabi, M Bailey, FE Bass, S Bin Kadiman, CJ McArthur, L Murray, MC Reade, IM Seppelt, J Takala, MP Wise, SA Webb
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2019
BACKGROUND: Dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU). The use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied. METHODS: In an open-label, randomized trial, we enrolled critically ill adults who had been undergoing ventilation for less than 12 hours in the ICU and were expected to continue to receive ventilatory support for longer than the next calendar day to receive dexmedetomidine as the sole or primary sedative or to receive usual care (propofol, midazol..View full abstract
Funded by the National Health and Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov number, NCT01728558.